X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS ALEMBIC PHARMA DR. DATSONS LABS/
ALEMBIC PHARMA
 
P/E (TTM) x -10.9 27.0 - View Chart
P/BV x 0.2 5.4 3.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   ALEMBIC PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
ALEMBIC PHARMA
Mar-18
DR. DATSONS LABS/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs126645 19.5%   
Low Rs31470 6.6%   
Sales per share (Unadj.) Rs133.0166.1 80.1%  
Earnings per share (Unadj.) Rs0.221.9 0.7%  
Cash flow per share (Unadj.) Rs6.627.5 24.0%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs128.8117.8 109.4%  
Shares outstanding (eoy) m31.66188.52 16.8%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.4 17.5%   
Avg P/E ratio x516.125.5 2,027.5%  
P/CF ratio (eoy) x11.820.3 58.4%  
Price / Book Value ratio x0.64.7 12.8%  
Dividend payout %018.3 0.0%   
Avg Mkt Cap Rs m2,477105,090 2.4%   
No. of employees `000NANA-   
Total wages/salary Rs m566,228 0.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,21131,308 13.4%  
Other income Rs m7970 111.9%   
Total revenues Rs m4,28931,378 13.7%   
Gross profit Rs m5696,431 8.8%  
Depreciation Rs m2041,055 19.4%   
Interest Rs m43034 1,265.3%   
Profit before tax Rs m135,413 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-81 2.2%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m61,204 0.5%   
Profit after tax Rs m54,128 0.1%  
Gross profit margin %13.520.5 65.7%  
Effective tax rate %48.022.2 216.0%   
Net profit margin %0.113.2 0.9%  
BALANCE SHEET DATA
Current assets Rs m6,85218,247 37.5%   
Current liabilities Rs m6,71111,235 59.7%   
Net working cap to sales %3.322.4 15.0%  
Current ratio x1.01.6 62.9%  
Inventory Days Days16186 188.0%  
Debtors Days Days31861 519.0%  
Net fixed assets Rs m3,67320,035 18.3%   
Share capital Rs m317377 84.0%   
"Free" reserves Rs m3,76121,824 17.2%   
Net worth Rs m4,07822,201 18.4%   
Long term debt Rs m1,6715,000 33.4%   
Total assets Rs m12,63339,411 32.1%  
Interest coverage x1.0160.2 0.6%   
Debt to equity ratio x0.40.2 181.9%  
Sales to assets ratio x0.30.8 42.0%   
Return on assets %3.410.6 32.6%  
Return on equity %0.118.6 0.6%  
Return on capital %7.719.7 38.9%  
Exports to sales %22.946.4 49.3%   
Imports to sales %14.310.5 136.1%   
Exports (fob) Rs m96414,535 6.6%   
Imports (cif) Rs m6023,288 18.3%   
Fx inflow Rs m96414,722 6.5%   
Fx outflow Rs m6077,026 8.6%   
Net fx Rs m3577,696 4.6%   
CASH FLOW
From Operations Rs m1,3453,124 43.0%  
From Investments Rs m-2,256-8,844 25.5%  
From Financial Activity Rs m-1,2005,026 -23.9%  
Net Cashflow Rs m-2,111-693 304.4%  

Share Holding

Indian Promoters % 4.5 74.1 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.9 -  
FIIs % 1.4 9.1 14.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 13.9 677.0%  
Shareholders   20,807 49,328 42.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  WOCKHARDT LTD.  VENUS REMEDIES  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - SUN PHARMA COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS